Dr. Stephen M. Treon, MD,PHD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 141 Ocoee St, Copperhill, TN 37317 Phone: 423-496-4103 Fax: 423-496-4106 |
News Archive
Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.
Bristol-Myers Squibb Company announced today the pricing terms of its previously announced cash tender offer for up to $750 million aggregate principal amount of certain of its outstanding debt securities.
Nuron Biotech Inc., a specialty biologics and vaccines company, today announced it has acquired from Pfizer Inc. Meningitec, which is a vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C.
CENTOGENE today announced that Evotec AG and CENTOGENE AG entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases.
› Verified 7 days ago